ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MREO

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma Group made false and/or misleading statements about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo BioPharma Group securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly. The deadline to serve as lead plaintiff is April 6, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].